Helicobacter pylori infection
Conditions
Interventions
VA Dual 14d Therapy Group (Study 1):Received vornorasen fumarate 20mg, 30min before meals, bid amoxicillin capsules, 1000mg, 30min after meals, and oral TID for 14d
VBAC Quadruple 14d Therapy Group (Study 1):Vonorasan fumarate 20mg, oral bid 30min before meals, bismuth potassium citrate capsules 240mg, 30min before meals, oral bid amoxicillin capsules 1000mg, 30m
VA Dual 14d Therapy Group (Study II):Received vornorasen fumarate 20mg, 30min before meals, bid amoxicillin capsules, 1000mg, 30min after meals, and oral TID for 14d
VBAM 14d Therapy Group (Study 2):Received vonorasan fumarate 20mg, oral bid bismuth potassium citrate capsule 240mg, oral bid 30min before meal, amoxicillin capsule 1000mg, 30min oral bid minocycline
L-VA dual 14d therapy group (Study 3):Received vornorasen fumarate 20mg, 30min before meals, bid amoxicillin capsules, 750mg, 30min after meals, and oral TID for 14d
L-VA-add 14d therapy group (Study 3):Received vornorrasan fumarate 20mg, oral bid 30min before meals, amoxicillin capsules 750mg, oral TID probiotics (Bifidobacterium triple viable 630mg bid or compou
H-VA Dual 14d Therapy Group (Study 3):Received vornorasen fumarate 20mg, 30min before meals, bid amoxicillin capsules, 1000mg, 30min after meals, and oral TID for 14d
VA Dual 10d Therapy Group (Study IV):Received vornorasen fumarate 20mg, oral bid 30min before meals, amoxicillin capsules 1000mg, 30min after meals, oral TID for 10d
VA-add 10d therapy group (Study 4):Received vonorasen fumarate 20mg, oral bid amoxicillin capsules 1000mg, 30min postprandial 30min oral TID probiotics(Bifidoba
Sponsors
Bejing Tongren Hospital, Capital Medical Uniersity
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years, gender is not limited (Study 6: age 60-75 years); 2. Those who are positive for Helicobacter pylori (positive for Helicobacter pylori on 13C/14C-UBT or histopathological examination); 3. Initial treatment
Exclusion criteria
Exclusion criteria: 1.Patients who have previously received treatment for Helicobacter pylori; 2.Patients allergic to any investigational drug; 3.Patients with significant organ dysfunction such as cardiac, respiratory, renal and nervous system diseases and malignant tumors, etc.; 4.Patients who have used antibiotics or bismuth within 4 weeks prior to enrollment, or acid suppressants within 2 weeks prior to enrollment; 5.Pregnant or lactating women; 6.Other situations that investigators believe unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hp eradication rate for the ITT analysis set;Hp eradication rate of the mITT analysis set;HP eradication rate for the PP analysis set; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment adherence; | — |
Countries
China
Contacts
Public ContactJianhong Chen
Bejing Tongren Hospital, Capital Medical Uniersity
Outcome results
None listed